We are investing in every aspect of #RadioligandTherapy (RLT) to deliver to patients. With a global footprint, industry-leading supply chain and clear vision for this treatment paradigm, we are committed to the present—and future—of RLTs.

#ReimagineMedicine

We are where we are today because people believed things were possible. Like eliminating a disease. We need to come together as the global #malaria community to finally outsmart the mosquito #WorldMalariaDay

For #Investors :
CEO Vas Narasimhan joined Carl Quintanilla on Money Movers to discuss strong Q1 #Earnings , driven from:
➡️ Product portfolio, new launches and growth drivers
➡️ Confidence in innovative medicines
➡️ Continued pipeline momentum
$NVS $NOVN #NVSQ124

CEO Vas Narasimhan discusses strong Q1 #Earnings on Bloomberg TV:
➡️ Confidence in outlook. Raises FY guidance
➡️ Performance in key brands across US, Europe, Japan & China
➡️ Scaling innovative medicines, incl. for cancer using advanced therapies
$NVS $NOVN #NVSQ124 #investors

For #Investors : Novartis is prioritizing an emerging technology platform called #RadioligandTherapy (RLT), with continued investment into new R&D capabilities and manufacturing scale.

$NVS $NOVN #NVSQ124

Q1 Earnings: A strong start to the year with continued momentum in our business and pipeline.

Performance across all key growth brands and geographies gives continued confidence in our mid- and long-term growth. Guidance raised for full year 2024.

$NVS $NOVN #NVSQ124

#NVSQ124 Novartis tweets on Q1 2024 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: go.novartis.social/3UrmjB4

$NVS $NOVN

Novartis will issue Q1 2024 results on Tuesday, Apr 23.

We invite #investors to our #earnings webcast to hear updates on our growth and performance.

$NVS $NOVN #NVSQ124

Every step of our #RadioligandTherapy (RLT) manufacturing process reflects our deep commitment to deliver these treatments to patients at the speed they need them. go.novartis.social/4aPmhJj

#ReimagineMedicine

Today, Indiana state officials, and professional and patient groups joined us for an opening ceremony event to celebrate our new #radioligandtherapy manufacturing facility in Indianapolis.
RLT is changing the way cancer is treated, and Novartis is proud to lead the way.

Our CEO Vas Narasimhan discusses business with David Rubenstein on Bloomberg TV, including:

➡️ The impact of AI on drug R&D
➡️ How recent acquisitions bolster our pipeline
➡️ New growth areas and innovations in medicine

Watch here: go.novartis.social/3IximUF

$NVS #Investors

In 2023, we reached over 280 million people with our medicines.

Entering our new era as an innovative medicines company, we work every day to restore possibilities for the millions of people living with major diseases.

$NVS #NVSFY23

#NVSFY23 Novartis tweets on Full Year and Q4 2023 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information go.novartis.social/3SF8H3l.

$NVS $NOVN

Novartis will issue Full Year and Q4 2023 results on Wednesday, Jan 31.

We invite #investors to our #earnings conference call to hear updates on our performance and strategy as a pure-play innovative medicines company.

$NVS $NOVN #NVSFY23

More than 2 million people are diagnosed with #LungCancer yearly, and each one has their own unique cancer journey. At Novartis, we are committed to improve patient outcomes through innovative medicines. Learn more this #LCAM : go.novartis.social/3SoGIpU

In drug development, confidence in your science makes it possible to choose bold approaches. Read how an unexpected approach to clinical studies showed how thinking big when the science is right can make all the difference.

The stigma surrounding #lungcancer is a real barrier to improving screening conditions and helping patients get the help they need. A focus on spreading awareness and encouraging education can help break down the attitudes toward lung cancer.

#Prostatecancer is a complex disease. At Novartis, we are committed to supporting education and awareness around prostate cancer to help those living with its realities feel empowered to take action for the care they want and deserve. novartis.social/60129Nbrg #Movember